BiotechTube

Bezuclastinib in combination with sunitinib

Phase 2Active
1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastrointestinal Stromal Tumors

Conditions

Gastrointestinal Stromal Tumors, GIST

Trial Timeline

Aug 1, 2024 → Jun 1, 2027

NCT ID
NCT06208748

About Bezuclastinib in combination with sunitinib

Bezuclastinib in combination with sunitinib is a phase 2 stage product being developed by Cogent Biosciences for Gastrointestinal Stromal Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT06208748. Target conditions include Gastrointestinal Stromal Tumors, GIST.

What happened to similar drugs?

8 of 20 similar drugs in Gastrointestinal Stromal Tumors were approved

Approved (8) Terminated (3) Active (9)
✅Remimazolam TosilateJiangsu Hengrui MedicineApproved
✅Mycophenolate SodiumNovartisApproved
✅myforticNovartisApproved
✅Imatinib MesylateNovartisApproved
✅Imatinib mesylateNovartisApproved
✅NilotinibNovartisApproved
✅Sunitinib Malate (SU011248)PfizerApproved

Hype Score Breakdown

Clinical
12
Activity
12
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06208748Phase 2Active

Competing Products

20 competing products in Gastrointestinal Stromal Tumors

See all competitors
ProductCompanyStageHype Score
Raludotatug Deruxtecan (R-DXd)Daiichi SankyoPhase 2
39
Patritumab deruxtecanDaiichi SankyoPhase 1/2
39
DS-6157aDaiichi SankyoPhase 1
21
DS-8201a + Physician's ChoiceDaiichi SankyoPhase 2
35
Naldemedine + PlaceboShionogiPhase 2
27
GemcitabineEli LillyPhase 1/2
32
OlaratumabEli LillyPhase 2
27
pemetrexed + cisplatinEli LillyPhase 2
35
cetuximabEli LillyPhase 2
35
BBI503Sumitomo PharmaPhase 2
27
BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + RegorafenibSumitomo PharmaPhase 1/2
32
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
40
Placebo + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol)Johnson & JohnsonPhase 2
35
Remimazolam TosilateJiangsu Hengrui MedicineApproved
43
Famitinib capsules + Sunitinib CapsulesJiangsu Hengrui MedicinePhase 3
32
FamitinibJiangsu Hengrui MedicinePhase 2
31
Esomeprazole IV + Omeprazole IVAstraZenecaPhase 3
40
Durvalumab + FLOT chemotherapyAstraZenecaPhase 3
44
EsomeprazoleAstraZenecaPhase 3
40
AZD2171AstraZenecaPhase 2
35